NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free ANGO Stock Alerts $5.85 +0.15 (+2.63%) (As of 10:27 AM ET) Add Compare Share Share Today's Range$5.73▼$5.8750-Day Range$5.27▼$6.2252-Week Range$5.26▼$12.62Volume52,847 shsAverage Volume502,080 shsMarket Capitalization$233.12 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get AngioDynamics alerts: Email Address AngioDynamics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside156.4% Upside$15.00 Price TargetShort InterestBearish6.17% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.04Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.44) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.03 out of 5 starsMedical Sector232nd out of 939 stocksSurgical & Medical Instruments Industry26th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, AngioDynamics has a forecasted upside of 156.4% from its current price of $5.85.Amount of Analyst CoverageAngioDynamics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.17% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in AngioDynamics has recently increased by 6.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 2.2 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search Interest2 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.44) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About AngioDynamics Stock (NASDAQ:ANGO)AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.Read More ANGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comAngioDynamics (ANGO) Set to Announce Quarterly Earnings on ThursdayMarch 19, 2024 | businesswire.comAngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) Sees Significant Growth in Short InterestMarch 19, 2024 | americanbankingnews.comAnalyzing KORU Medical Systems (NASDAQ:KRMD) and AngioDynamics (NASDAQ:ANGO)March 18, 2024 | americanbankingnews.comAngioDynamics, Inc. to Post Q3 2024 Earnings of ($0.15) Per Share, Zacks Research Forecasts (NASDAQ:ANGO)March 6, 2024 | businesswire.comAngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services ConferenceMarch 4, 2024 | investorplace.comHidden Gems: 7 Oversold Stocks Ready for a Major ReboundMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 1, 2024 | finance.yahoo.comAngioDynamics (ANGO) Gains But Lags Market: What You Should KnowFebruary 18, 2024 | investing.comAngioDynamics sells PICC and Midline portfolios for $45 millionFebruary 17, 2024 | finance.yahoo.comELV Feb 2024 410.000 putFebruary 16, 2024 | msn.comAngioDynamics divests PICC, Midline product portfolioFebruary 16, 2024 | finance.yahoo.comAngioDynamics (ANGO) Divests Its PICC & Midline BusinessesFebruary 15, 2024 | marketwatch.comAngioDynamics Sells PICC, Midline Products for Up to $45 MillionFebruary 15, 2024 | finance.yahoo.comAngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionFebruary 15, 2024 | businesswire.comAngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionFebruary 9, 2024 | finance.yahoo.comAngioDynamics (ANGO) Stock Sinks As Market Gains: Here's WhyJanuary 25, 2024 | finance.yahoo.comAngioDynamics' (ANGO) New XL Catheter to Help in PAD TreatmentJanuary 23, 2024 | msn.comAngioDynamics gets FDA clearance for Auryon XL catheterJanuary 23, 2024 | markets.businessinsider.comAngioDynamics Receives FDA 510(k) Clearance For Auryon XL CatheterJanuary 23, 2024 | finance.yahoo.comAngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial DiseaseJanuary 19, 2024 | ca.finance.yahoo.comAngioDynamics, Inc. (ANGO)January 9, 2024 | markets.businessinsider.comRaymond James Maintains Outperform Rating for AngioDynamics: Here's What You Need To KnowJanuary 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO)January 8, 2024 | markets.businessinsider.comBuy Rating Maintained for AngioDynamics Amidst Strategic Restructuring and New Product LaunchesJanuary 8, 2024 | finance.yahoo.comAngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues MissSee More Headlines Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/05/2024Today3/28/2024Next Earnings (Confirmed)4/04/2024Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees815Year Founded1988Price Target and Rating Average Stock Price Target$15.00 High Stock Price Target$18.00 Low Stock Price Target$10.00 Potential Upside/Downside+156.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,440,000.00 Net Margins-4.28% Pretax Margin-2.82% Return on Equity-1.78% Return on Assets-1.38% Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio1.55 Sales & Book Value Annual Sales$338.75 million Price / Sales0.69 Cash Flow$1.19 per share Price / Cash Flow4.93 Book Value$9.64 per share Price / Book0.61Miscellaneous Outstanding Shares39,850,000Free Float37,822,000Market Cap$233.12 million OptionableOptionable Beta0.66 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. James C. Clemmer (Age 60)CEO, President & Director Comp: $982.92kMr. Stephen A. Trowbridge (Age 50)Executive VP & CFO Comp: $528.02kMr. Chad T. Campbell (Age 53)Senior VP and GM of Vascular Access & Oncology Global Business Unit Comp: $416.51kMs. Laura Piccinini (Age 55)Senior VP & GM of International Comp: $444.31kMr. Saleem M. CheeksVice President of CommunicationsMr. Benjamin H. Davis (Age 60)Senior Vice President of Business Development Ms. Marna I. Bronfen-Moore (Age 57)Senior Vice President of Human Resources Mr. Warren G. Nighan (Age 55)Senior Vice President of Quality & Regulatory Affairs Comp: $622.11kMs. Kim L. Seabury (Age 57)Senior Vice President of Information Technology Mr. Scott Centea (Age 45)Senior VP & GM of Endovascular Therapies Comp: $558.54kMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYSeaSpineNASDAQ:SPNECytosorbentsNASDAQ:CTSOSurmodicsNASDAQ:SRDXPulse BiosciencesNASDAQ:PLSEView All CompetitorsInstitutional OwnershipPNC Financial Services Group Inc.Sold 2,272 shares on 3/22/2024Ownership: 0.037%Vanguard Group Inc.Bought 136,323 shares on 3/11/2024Ownership: 5.692%Goldman Sachs Group Inc.Sold 396,419 shares on 3/1/2024Ownership: 0.488%Public Employees Retirement System of OhioBought 13,500 shares on 2/16/2024Ownership: 0.192%Price T Rowe Associates Inc. MDBought 5,131 shares on 2/16/2024Ownership: 0.078%View All Institutional Transactions ANGO Stock Analysis - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price target for 2024? 3 brokers have issued twelve-month target prices for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $18.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2024? AngioDynamics' stock was trading at $7.84 at the beginning of the year. Since then, ANGO shares have decreased by 25.4% and is now trading at $5.85. View the best growth stocks for 2024 here. Are investors shorting AngioDynamics? AngioDynamics saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,460,000 shares, an increase of 7.0% from the February 29th total of 2,300,000 shares. Based on an average daily trading volume, of 502,000 shares, the days-to-cover ratio is presently 4.9 days. View AngioDynamics' Short Interest. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ANGO earnings forecast. How can I listen to AngioDynamics' earnings call? AngioDynamics will be holding an earnings conference call on Thursday, April 4th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13745239". How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Friday, January, 5th. The medical instruments supplier reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. The medical instruments supplier had revenue of $79.07 million for the quarter, compared to the consensus estimate of $81.65 million. AngioDynamics had a negative net margin of 4.28% and a negative trailing twelve-month return on equity of 1.78%. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics updated its FY 2024 earnings guidance on Friday, January, 5th. The company provided EPS guidance of -0.420--0.350 for the period, compared to the consensus earnings per share estimate of -0.320. The company issued revenue guidance of $320.0 million-$325.0 million, compared to the consensus revenue estimate of $329.1 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.69%), Vanguard Group Inc. (5.69%), Dimensional Fund Advisors LP (3.74%), Armistice Capital LLC (2.01%), Fund 1 Investments LLC (1.25%) and Nuveen Asset Management LLC (1.08%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More This page (NASDAQ:ANGO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.